Main menu

Precision cell engineering enabled through nanopore sequencing


Abstract
Optimizing the biomanufacturing of therapeutic molecules is crucial for efficient patient treatment. The initial step in this production pipeline involves constructing Chinese hamster ovary (CHO) cell lines expressing biologics molecules, which are under continuous development to improve traits such as titer and stability. Lonza has recently adopted nanopore long-read sequencing to enhance cell line engineering and biomarker discovery. This presentation will discuss the latest advancements in improving omics data accuracy through de novo genome assembly, and the integration of nanopore whole-genome sequencing and DNA methylation analysis with next-generation sequencing technologies. This integration provides an in-depth multiomics characterization of Lonza’s CHO cell lines, offering comprehensive insights into their genetic and epigenetic landscapes.

Biography
Daniel Fabian heads the Bioinformatics Innovation team at Lonza Biologics R&D in Cambridge, UK, leading multiomics data integration and predictive modeling to optimize biomanufacturing. Originally from Vienna, Austria, he earned a biotechnology degree in 2010 and a PhD in population genetics in 2014. With over 10 years of experience researching the genetic basis of immunity and aging at institutions, including the University of Cambridge and EMBL-EBI, Daniel joined Lonza in 2021 to advance cell line engineering and biomarker discovery.

Authors: Daniel Fabian

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

ナノポア技術

ナノポアの最新ニュースを購読 リソースと発表文献 Nanopore Communityとは

Oxford Nanoporeについて

ニュース 会社沿革 持続可能性 経営陣 メディアリソース & お問い合わせ先 投資家向け パートナー向け Oxford Nanopore社で働く 現在の募集状況 営業上の情報 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag